Bumame Farmasi

What Bumame Farmasi does

Bumame Farmasi is an Indonesian for-profit healthcare services company headquartered in Jakarta, founded in 2020 amid the COVID-19 pandemic. According to its publicly stated mission, the company provides COVID-19 health test services intended to support pandemic prevention and limit virus transmission. It operates with 251-500 employees, implying a multi-site or large-scale testing operation rather than a single clinic, though the precise number and locations of testing sites are not documented in the available data.

The company's revenue model is not disclosed in the extractable data, but the implied unit economics are consistent with a high-volume, consumer-facing diagnostic testing service — likely a mix of walk-in testing, corporate/employer-mandated screening, and possibly outbound/home-visit sample collection. The brand name "Farmasi" (Indonesian for "pharmacy") and its persistence beyond the acute pandemic phase suggest an intent or actual pivot toward broader consumer health diagnostics or retail pharmacy services, though no confirmed products, pricing, or partnership data are available to validate this.

The broader information profile of the company is extremely thin. The corporate website (bumamefarmasi.com) returned a verification/loading page at the time of data collection, blocking extraction of leadership, ownership, funding history, customer logos, certifications, partnerships, and financial details. There are no records of funding rounds, mergers, acquisitions, regulatory actions, management team, or notable partnerships in the supplied data. This represents a material due diligence gap: any investment-grade assessment of Bumame Farmasi would require primary-source verification of its current operating status, post-pandemic business model evolution, ownership structure, and financial trajectory.

Name

Bumame Farmasi

Website

https://bumamefarmasi.com

Company type

Private

Founded year

2020

Headcount range

251–500 employees

Short description

Bumame Farmasi is an Indonesia-based, Jakarta-headquartered healthcare services company founded in 2020 that provides COVID-19 health testing to support pandemic prevention, operating with 251-500 employees. The brand name suggests a broader pharmacy and consumer health diagnostics orientation beyond COVID testing.

Ownership category

akta.pro rank

Product category

Diagnostic Testing Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)

SIC

Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)

akta.pro primary industry

Pathogen & Disease Diagnostics Services (Plant, Soil, Water) (AFACAKAG)

akta.pro secondary industry

Sanitation, Exclusion & Pest-Proofing Consulting (HACCP/FSMA Support) (AFACAGAI)

Keywords

• COVID-19 testing services
• Diagnostic health screening
• Retail pharmacy services
• Pandemic health testing
• Consumer health diagnostics

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure

Core offering

Bumame Farmasi provides COVID-19 health test services aimed at supporting pandemic prevention and limiting the spread of the virus. Operating from Jakarta, Indonesia, the company functions as a pharmacy and diagnostic testing provider serving individual consumers seeking screening tests during the pandemic period.

Differentiator

Problem solved

Functional benefit

Products and services

• COVID-19 Health Testing Services Screening and diagnostic COVID-19 tests offered to individual consumers in Jakarta to support pandemic prevention and limit virus transmission.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights3 records

Direct peers

• Prodia Widyahusada: Indonesia's largest clinical laboratory network offering a broad menu of diagnostic tests across multiple cities. Directly comparable as a domestic diagnostic services provider competing for the same outpatient testing demand.
• Biotest Indonesia: Indonesian clinical laboratory services provider offering a range of medical diagnostics. Direct competitor in the Indonesian outpatient testing market with overlapping service portfolio.
• Kimia Farma Diagnostika: Subsidiary of state-owned Kimia Farma operating clinical laboratories and pharmacy-linked diagnostic services across Indonesia. Comparable as a pharmacy-adjacent diagnostic provider, mirroring Bumame Farmasi's 'Farmasi' positioning.
• Laboratorium Klinik Pramita: Established Indonesian clinical laboratory chain providing routine and specialized diagnostic testing. Comparable in core service offering, target customer (referring physicians and patients), and Indonesian market focus.

Broad incumbents

• Siloam International Hospitals: Largest private hospital operator in Indonesia with in-house laboratory services. Comparable as a broader Indonesian healthcare services provider with integrated diagnostic capability and large patient flow.
• Biofarma: State-owned Indonesian life sciences company primarily focused on vaccine manufacturing but with adjacent diagnostic and health service capabilities. Comparable as a large domestic healthcare player operating in overlapping segments.

Emerging players

• Alodokter: Indonesian health-tech platform connecting patients to doctors, clinics, and diagnostic services. Comparable in addressing Indonesian consumer health-services demand via digital channels, partially overlapping with Bumame's outpatient testing customer base.
• Halodoc: Indonesian digital health platform offering teleconsultations, pharmacy delivery, and home-based lab testing services. Comparable as a Jakarta-based health services platform addressing similar consumer-facing testing and pharmacy demand.

Regional players

• Pathology Asia (Singapore-based regional labs): Regional clinical laboratory operator with presence across Southeast Asia. Comparable in service category and Southeast Asian operating context, but primarily serves markets outside Indonesia.
• Metropolis Healthcare: Large pan-India diagnostic chain offering clinical laboratory services. Comparable as an emerging-market diagnostic services operator with comparable scale and outpatient testing model, though geographically focused on India.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bumame Farmasi